NEW YORK (GenomeWeb News) – Greg Lucier, chairman and CEO of Invitrogen, will assume that some role following consummation of the firm’s merger with Applied Biosystems. Mark Stevenson, currently president and COO of ABI, will retain that role in the merged company, which will keep the ABI name. Tony White, chairman, president, and CEO of ABI parent Applera, will serve as a consultant to ABI following the deal.
 

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.